Key messages
- •
Cardiovascular disease has an atypical nature in renal transplant recipients when compared with the general and dialysis population
- •
Available data support the use of statins, and standard interventions, in the management of coronary disease in transplant recipients
- •
In the management of hypertension, there are no data to favour one agent over another, and blood-pressure targets have been adopted from the chronic kidney disease population guidelines
- •
New-onset diabetes is a major, potentially modifiable risk factor for cardiovascular disease in transplant recipients
- •
Minimisation or avoidance of corticosteroids or calcineurin inhibitors can reduce lipid concentrations, blood pressure, and risk of diabetes, but has a restricted role in the management of cardiovascular disease after transplantation